A Prescriber’s Guide to Compounded HRT: Formulations, Dosing, and How to Order

Hormone replacement therapy compounding represents the single largest category in compounding pharmacy, accounting for approximately 36% of all compounding prescriptions nationally according to the Alliance for Pharmacy Compounding. For prescribers in family medicine, OB/GYN, endocrinology, and integrative medicine, compounded HRT fills a specific clinical need: providing hormone preparations in formulations, dosage forms, and strengths that FDA-approved products do not cover.

This guide walks through the clinical landscape of compounded HRT prescribing—from when compounding is clinically appropriate, to the formulations and dosage forms available, to how prescribers can select quality compounding partners and streamline the ordering process.

When Compounded HRT Is Clinically Appropriate

FDA-approved hormone therapy products should be the starting point for most patients. Dozens of FDA-approved estrogen, progesterone, and testosterone products are available in various strengths and delivery systems, and these products have undergone rigorous review for safety, efficacy, and manufacturing consistency. Both ACOG and the Endocrine Society recommend FDA-approved formulations as first-line therapy when they meet the patient’s clinical needs.

Compounded HRT becomes clinically relevant when FDA-approved options are insufficient for a specific patient’s situation. Common clinical scenarios include:

Allergy or sensitivity to inactive ingredients. A patient may react to a dye, preservative, filler, or adhesive in a commercial product. Compounding allows the formulation to exclude the specific allergen while delivering the same active ingredient.

Need for a non-standard strength. FDA-approved products come in fixed doses. Some patients require titration to a strength between commercially available options, or need a starting dose lower than the lowest commercial product offers. Compounding allows precise dose customization.

Preferred dosage form not commercially available. A patient may need a topical cream when only oral capsules are available in the needed hormone, or a sublingual preparation when they cannot tolerate oral delivery. Compounding expands the dosage-form options beyond what the commercial market provides.

Combination therapy in a single preparation. Some prescribers prefer to combine multiple hormones (e.g., estriol and estradiol, or estrogen with progesterone) into a single preparation to simplify the patient’s regimen. While evidence supporting specific multi-hormone combinations is limited, this approach is widely used in clinical practice when single-agent commercial products would require the patient to use multiple separate products.

Important clinical note: Prescribers should counsel patients that compounded preparations are not FDA-approved, that quality can vary between pharmacies, and that the evidence base for specific compounded formulations is more limited than for FDA-approved products. These are essential elements of informed consent when prescribing compounded HRT.